Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(9):683-684; doi:10.1093/jnci/92.9.683
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 9, 683-684, May 3, 2000
© 2000 Oxford University Press

NEWS

Herceptin in the Adjuvant Setting: Phase III Trials Begin

Caroline McNeil

Herceptin research took a long-expected next step in March with the opening of the first large randomized trial to evaluate the monoclonal antibody as the initial treatment in non-metastatic breast cancer.

The trial will pit chemotherapy with cyclophosphamide, adriamycin, and paclitaxel against the same three drugs plus Herceptin as adjuvant treatment for node-positive tumors. The National Surgical Adjuvant Breast and Bowel Project is conducting the study.

A second phase III trial, an intergroup study led by the North Central Cancer Treatment Group, will follow soon. . . . [Full Text of this Article]

Tumor Response

Looking for Markers

Tamoxifen Question


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
B.-H. Bay, R. Jin, J. Huang, and P.-H. Tan
Metallothionein as a prognostic biomarker in breast cancer.
Experimental Biology and Medicine, October 1, 2006; 231(9): 1516 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al.
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
J Natl Cancer Inst, May 19, 2004; 96(10): 759 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, K. Shirakawa, S. Kawamoto, T. Saga, N. Sato, A. Hiraga, I. Watanabe, Y. Heike, K. Togashi, J. Konishi, et al.
Rapid Accumulation and Internalization of Radiolabeled Herceptin in an Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-enhanced Dynamic MRI with the Macromolecular Contrast Agent G6-(1B4M-Gd)256
Cancer Res., February 1, 2002; 62(3): 860 - 866.
[Abstract] [Full Text] [PDF]